Background Nivolumab is an anti–PD-1 antibody that restores the antitumour immune function of T cells, blockingthe binding of PD-1 with its ligand PD-L1. PD-1 is expressed on T cells and interacts with PD-L1 on tumour cells.The PD-1–PD-L1 link inhibits T cell activation. In metastatic melanoma, PD-1–PD-L1 binding plays a critical role,and the advent of the immune checkpoint inhibitor nivolumab has delivered new and effective treatment optionswith proven clinical benefit. In the present study, we evaluated the efficacy of nivolumab in elderly patients withmetastatic melanoma.Methods The study enrolled 55 elderly patients (75 years of age and older) with a diagnosis of metastatic melanoma.Primary endpoints of the study were progression-free survival (pfs) and the objective response rate; secondaryendpoints were overall survival, reduction in serum lactate dehydrogenase (ldh) from before to after treatment,and tolerability.Results Nivolumab was well tolerated and resulted in good disease control, with a manageable toxicity profile andsignificant clinical benefit. The duration of pfs was 5.1 months (95% confidence interval: 3.5 months to 6.8 months).A significant correlation was observed between reduction in serum ldh and pfs: 0.60 (95% confidence interval: 0.28to 0.86; p = 0.002).Conclusions Nivolumab is an immunotherapy treatment that has proved to be an effective and well-toleratedtherapeutic option in elderly patients with metastatic melanoma.Key Words Nivolumab; melanoma, metastatic; elderly patients; immunotherapy; quality of life; clinical benefit;lactate dehydrogenase
Lingua originaleEnglish
pagine (da-a)e75-e80
Numero di pagine5
RivistaCurrent Oncology
Stato di pubblicazionePublished - 2020


Entra nei temi di ricerca di 'Nivolumab in metastatic melanoma: good efficacy and tolerability in elderly patients'. Insieme formano una fingerprint unica.

Cita questo